Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.

• मुख्य लेखकों: Jason W Bennett (लेखक), Anjali Yadava (लेखक), Donna Tosh (लेखक), Jetsumon Sattabongkot (लेखक), Jack Komisar (लेखक), Lisa A Ware (लेखक), William F McCarthy (लेखक), Jessica J Cowden (लेखक), Jason Regules (लेखक), Michele D Spring (लेखक), Kristopher Paolino (लेखक), Joshua D Hartzell (लेखक), James F Cummings (लेखक), Thomas L Richie (लेखक), Joanne Lumsden (लेखक), Edwin Kamau (लेखक), Jittawadee Murphy (लेखक), Cynthia Lee (लेखक), Falgunee Parekh (लेखक), Ashley Birkett (लेखक), Joe Cohen (लेखक), W Ripley Ballou (लेखक), Mark E Polhemus (लेखक), Yannick F Vanloubbeeck (लेखक), Johan Vekemans (लेखक), Christian F Ockenhouse (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Public Library of Science (PLoS), 2016-02-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

A vaccine to prevent infection and disease caused by Plasmodium vivax is needed both to reduce the morbidity caused by this parasite and as a key component in efforts to eradicate malaria worldwide. Vivax malaria protein 1 (VMP001), a novel chimeric protein that incorporates the amino- and carboxy-...